Multicenter phase II trial of brequinar sodium in patients with advanced melanoma
- PMID: 1450049
- DOI: 10.1093/oxfordjournals.annonc.a058298
Multicenter phase II trial of brequinar sodium in patients with advanced melanoma
Abstract
Seventeen patients with advanced melanoma and no prior exposure to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given at a median weekly dose of 1200 mg/m2 intravenously. In 14 patients evaluable for efficacy, there were no objective responses. The toxicity was moderate. We conclude that, at this dose and schedule, brequinar has no activity in advanced melanoma.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
